design of this study is a cross-sectional study using secondary data. The sampling frame will include high school students. The method of sample selection used is the clustering sampling method. The unit of analysis is at the individual level. The study population is high school students. The dependent variable is weight and independent variables are: height, diet, nutrition, exercising, age, sex, race and self-perception. RESULTS: The model was very representational of the study population \( r^2 = 0.584 \). The statistical significance level was 0.05 and many variables (Height, Gender, Ethnicity, Age, etc.) proved to have a strong significant effect on weight (Beta was also used). CONCLUSIONS: The limitation of the study is that the survey fails to ask any question regarding genetic disorders that influence excessive weight gain, obesity. This information would be formable in trying to treat adolescents who currently suffer from genetic disorders. Also this would provide a good estimate of the percentage of young people (by ethnicity) who are affected. Another survey is recommended; that ask an assortment of questions pertaining to the daily habits of adolescents, a social behavioral study. The information could aid in the development of a better behavioral treatment for children in accordance to their life style. The Youth Risk Behavioral Survey needs to be modified so that it is more inclusive. The survey should be translated into other languages and made available for students who are not fluent in comprehending English. Non-English speaking children do gain weight as well.

DOES THE RATE OF MEDICARE MANAGED-CARE PENETRATION AFFECT AVAILABILITY OF RESOURCES FOR HEART FAILURE TREATMENT?

Masseлинк LE, Friedman JY, Whellan DJ, Schulman KA

1Duke Clinical Research Institute, Durham, NC, USA; 2Duke University Medical Center, Durham, NC, USA

OBJECTIVES: The HF-ACTION trial evaluates the effectiveness of exercise as an intervention for heart failure patients. To assess generalizability of study findings, we included a survey of participants' exercise habits and services. METHODS: The HF-ACTION trial evaluates the effectiveness of exercise as an intervention for heart failure patients. To assess generalizability of study findings, we included a survey of participants' exercise habits and services. RESULTS: Fifty-six and 51 patients underwent open and laparoscopic bypass surgeries respectively. The mean BMI is 53.96 with minimum of 36.1 and maximum of 85.2 with the mean overall LOS being 4.22 days with minimum of 2 and maximum 28 days. The mean LOS for open and laparoscopic gastric bypass surgery is 5 and 3 days respectively. The mean operating time for the open and laparoscopic methods are 165 and 175 minutes respectively. LOS is positively correlated with BMI (\( r < 0.05, r = 0.248 \)), the number of pre-existing medical conditions (\( r < 0.05, r = 0.218 \)), open surgery (\( r < 0.01, r = 0.323 \)) but negatively correlated with laparoscopic surgery (\( r < 0.01, r = -0.306 \)) while intensive care usage is positively correlated with BMI and open surgery (\( r < 0.01, r = 0.350 \) and 0.250) but is negatively correlated with laparoscopic procedures (\( r < 0.01, r = -0.266 \)). Pulse rates greater than 110/minute on second and third post-operative days is associated with total operating time (\( r < 0.01, r = 0.370 \)) and with post-operative leak from anastomosis on first and third post-operative days (\( r < 0.05 \) and 0.272) respectively. BMI is also positively associated with public aid patients but is negatively associated with private payers. CONCLUSION: Being an increasingly popular surgery for obese people, gastric bypass procedures need to be carefully evaluated long-term for optimum clinical and economic outcomes in view of the above findings.

GASTRIC BYPASS SURGERY—AN OVERVIEW

Misra S

Rush University Medical Center, Chicago, IL, USA

OBJECTIVE: Evaluating gastric bypass surgery in obese patients. METHODS: From March 1999 to December 2002, 106 obese patients underwent gastric bypass operations by a single surgeon in a tertiary care hospital in the Midwest. The data is extracted from the clinical charts and evaluated statistically using SPSS software. The relationship between body mass index (BMI) of patients, type of operation performed, operating time, length of stay (LOS) in the hospital, presence of co-morbidities and payer type are analyzed. RESULTS: Fifty-six and 51 patients underwent open and laparoscopic bypass surgeries respectively. The mean BMI is 33.96 with minimum of 16.1 and maximum of 52.2 with the mean overall LOS being 4.22 days with minimum of 2 and maximum 28 days. The mean LOS for open and laparoscopic gastric bypass surgery is 5 and 3 days respectively. The mean operating time for the open and laparoscopic methods are 165 and 175 minutes respectively. LOS is positively correlated with BMI (\( r < 0.05, r = 0.248 \)), the number of pre-existing medical conditions (\( r < 0.05, r = 0.218 \)), open surgery (\( r < 0.01, r = 0.323 \)) but negatively correlated with laparoscopic surgery (\( r < 0.01, r = -0.306 \)) while intensive care usage is positively correlated with BMI and open surgery (\( r < 0.01, r = 0.350 \) and 0.250) but is negatively correlated with laparoscopic procedures (\( r < 0.01, r = -0.266 \)). Pulse rates greater than 110/minute on second and third post-operative days is associated with total operating time (\( r < 0.01, r = 0.370 \)) and with post-operative leak from anastomosis on first and third post-operative days (\( r < 0.05 \) and 0.272) respectively. BMI is also positively associated with public aid patients but is negatively associated with private payers. CONCLUSION: Being an increasingly popular surgery for obese people, gastric bypass procedures need to be carefully evaluated long-term for optimum clinical and economic outcomes in view of the above findings.

RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT

Thaker DJ, Godley Pj, Browne BA, Rohack J, Houck P

Scott & White, Temple, TX, USA

OBJECTIVE: Beta-blocker utilization in patients with mild to moderate congestive heart failure (CHF) substantially improves left ventricular ejection fraction and patient symptoms and reduces overall mortality. Carvedilol and extended-release metoprolol succinate are the only beta-blocking agents currently indicated in the US for CHF patients. Both agents have shown similar risk reduction in overall and cause-specific mortality; however, no comparative outcomes data for the two agents are available. This study identifies current utilization patterns (agent/dosing regimens) of beta-blocker therapy in the CHF population at Scott & White Health Plan. METHODS: Health plan pharmacy claims data were retrospectively reviewed for calendar year 2002 for beta-blocker prescribing patterns for CHF patients (identified by ICD-9 codes). Specifically, pharmacy claims were evaluated for inclusion of beta-blockers as standard therapy for CHF, use of FDA-approved versus off-label use of beta-blockers for CHF, and use of recommended doses. RESULTS: Approximately 1700 health plan CHF patients were identified; 40% of those

PCV50

PCV49

PCV51
patients had a prescription filled for a beta-blocker during 2002. Of the CHF patients receiving a beta-blocker, less than 45% were prescribed either of the two indicated agents (carvedilol or extended-release metoprolol succinate) for CHF. Furthermore, less than 40% of patients prescribed either carvedilol or extended-release metoprolol succinate achieved target CHF doses. Thus, of those CHF patients currently on beta-blocker therapy, less than 17% received an appropriate regimen. CONCLUSIONS: This evaluation illustrates that less than ten percent of CHF patients in this managed care plan are receiving optimal beta-blocker therapy. Future quality improvement efforts should be focused on provider-based educational initiatives to improve beta-blocker prescribing patterns in the CHF population. Increased use of beta-blocker therapy in patients identified with CHF would significantly improve the morbidity and mortality associated with this disease.

**PCV52**

**IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERNS IN A CALIFORNIA MEDICAID POPULATION**

Nichol MB1, Shi S1, Knight TK2, Popovian R3, Moriza R2

1University of Southern California, Los Angeles, CA, USA; 2Pfizer, Inc, New York, NY, USA

OBJECTIVES: To investigate statin usage patterns in terms of continuation, switch and/or augmentation, and to associate these patterns with changing market conditions. METHODS: The study is based on a 20% sample of California Medicaid (Medi-Cal) fee-for-service claims on statin prescriptions from 1995 through 2002. The length of the first statin therapy phase is presented with Kaplan-Meier curves. The switch and/or augmentation pattern is studied by tracking each patient for 12 months from the date of the first fill (index date). Results are presented by the year of index date. There are six statins included in the study: Cerivastatin, Fluvastatin, Atorvastatin, Lovastatin, Pravastatin and Simvastatin. RESULTS: Atorvastatin (N = 15,686, Median survival days = 244) and Simvastatin (N = 9162, Median survival days = 200) had longer therapy phases while Cerivastatin (N = 2022, Median survival days = 101) and Lovastatin (N = 8910, Median survival days = 99) had shorter therapy phases. About 40% of Atorvastatin and Simvastatin patients were still on their initial medication after one year, but only 20% of patients initiated on Lovastatin or Cerivastatin remained on their medication. The introduction of Atorvastatin was associated with a sudden increase of switch/augmentation events among patients initiated on other statin brands. When Cerivastatin was withdrawn from the US market and Lovastatin was phased out of the Medi-Cal formulary, the proportion of switch/augmentation events also increased. CONCLUSIONS: The introduction of Atorvastatin, the withdrawal of Cerivastatin and the phase-out of Lovastatin may be key factors in statin persistence patterns. Market forces should not be overlooked when analyzing medication compliance and medication usage patterns. Because changes in the market are more likely to be unique events, their effect may overshadow other adjustments in comparison of medication compliance.

**PCV53**

**IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS**

Liu X, Yu W, Yokoyama K

WellPoint Pharmacy Management, West Hills, CA, USA

OBJECTIVES: To analyze the changes in utilization and prescribing patterns of antihypertensive drugs before and after the publication of the ALLHAT results in 2002 that recommended the use of thiazide diuretics in new starts. METHODS: Utilizing pharmacy claims, member and provider data from a managed care plan of over 2 million members, this study selected two cohorts of patients who received two or more claims for anti-hypertensive or diuretic products from the same providers in the first 9 months of 2002 (Period 1) or the first 9 months of 2003 (Period 2). The providers who prescribed antihypertensive or diuretic medications for both periods were included. The patients were continuously enrolled adults who did not receive any anti-hypertensive or diuretic products in the 3 months prior to index date. Changes in physician prescribing patterns for initiation of hypertension treatment in Period 1 and Period 2 were analyzed. Utilization of different medications between the two periods, especially the likelihood of receiving thiazide diuretics, was also examined. RESULTS: The study identified 7605 physicians who prescribed antihypertensive drugs to 25,519 patients in Period 1 and 26,300 patients in Period 2. Across the two periods, the percentage of physicians who prescribed any thiazide diuretics increased from 14.5% to 16.1% (p < 0.01), while utilization of ACE inhibitors or CCBs as initial treatment decreased approximately 2% (p < 0.01). A logistic regression model indicated that patients in Period 2 were 22.8% more likely to receive thiazide diuretics and 9.9% more likely to receive any diuretics than patients in Period 1 (p < 0.01), controlling for demographics, comorbidities measured by chronic disease scores (CDS), and provider specialties. CONCLUSION: ALLHAT results increased prescribing of thiazide diuretics as initial treatment of hypertension.

**PCV54**

**IMPACT OF THE NATIONAL SERVICE FRAMEWORK (NSF) FOR CORONARY ARTERY DISEASE (CAD) ON PHYSICIAN COMPLIANCE OF PRESCRIBING ASPIRIN AND STATINS FOR SECONDARY PREVENTION IN THE UNITED KINGDOM (UK)**

Pradhan A1, Ray S2, Casio P

1Bristol Myers Squibb, London, United Kingdom; 2Bristol Myers Squibb, Wallingford, CT, USA

OBJECTIVE: The NSF guidelines for CAD, introduced in March 2000 in the UK, advocate that by April 2002, 80–90% of the patients discharged from hospital following myocardial infarction (MI) should be receiving prescriptions for aspirin and statins for secondary prevention. A time-trend analysis was performed to assess the impact of NSF on physician compliance with the prescribing guidelines. METHODS: The UK-Mediplus, a nationally representative general-practitioner database was used to identify all individuals with diagnosis of their first MI (index-date) between April 1997 and March 2003, and surviving at least 90 days following the index-date. Patients receiving at least one prescription of statin and aspirin, linked to their MI diagnosis, during the 90-day follow-up period were considered NSF-compliant with those drugs respectively. Annual trends in proportion of NSF-compliant patients, for aspirin, statins and aspirin-statin combination, were compared between pre- and post-NSF (after March 2000) periods. Logistic regression was used to estimate the effect of age and gender on compliance. RESULTS: Of 8598 eligible first-MI patients with a mean age of 70.4 (S.D. = 13.2), 65.5% were males, and 67.2% were elderly (age 65+). Aspirin-statin combination use increased from 13.7% to 23.5% between April 1997 and March 2000, and increased to 42.1% by March 2003. Aspirin and statin use alone were 49.5% and 71.6% respectively by end of March 2003. Relative to non-elderly, the elderly were less likely to receive aspirin-statin combination. However, the odds ratio (OR) for the elderly receiving combination improved during post-NSF period (OR = 0.64, p < 0.05